ABSTRACT
To further evaluate the efficacy and toxicity of the gamma-ray stereotactic body radiation therapy [gamma-SBRT] in patients with stage I/II non-small-cell lung cancer [NSCLC]. Twenty-nine newly diagnosed patients with stage I/II NSCLC who had no previous treatments, underwent OUR-QGD type of the gamma-SBRT at the Radiation Oncology Department, People's Liberation Army Airforce General Hospital, Beijing, China from January 2007 to July 2010. All patients were immobilized by vacuum bag, and then a slow CT scan was performed without any respiration gating. The total radiation dose of 50%, 60%, and 70% isodose line were prescribed in 50, 60, and 70 Grey [Gy] correspondingly, covering 100% of the planning target volume [PTV], 90% of the clinical target volume [CTV], and 80% of the gross target volume [GTV] in 10 fractions. The CT scans of the chest were required at one, 3, 6, 12, 18, and 24 months to evaluate the efficacy of the treatment. The median follow-up duration was 24 months, and the final follow-up rate is 96.6%. Local control rates of one and 2 years were all 93.1%. The progression-free survival rates versus overall survival rate of one year was 89.7% versus 96.6%, and 2 years was 86.1% versus 89.4%. Acute radiation reactions was diagnosed in 34.5%, and late radiation reactions in 37.9% of patients. The gamma-SBRT results in a good curative effects, and minimal toxicity in the treatment of stage I/II NSCLC